A vinca alkaloid.
A semisynthetic vinca alkaloid and an inhibitor of microtubule polymerization with anti-tumor properties across the spectrum of cancers.
Typically induces objective responses in at least one third of patients with advanced breast cancer.
Single agent vinovelbine has produced response rate of 40-60% and 15-20% in first line and second line settings of breast cancer, respectively.
Associated with a 30% response rate for non-small cell lung cancer.
Majority of vinorelbine metabolism occurs in the liver with the majority of the drug is excreted un changed in bile.
Has demonstrated clinical activity in lymphoma, multiple myeloma, small cell lung cancer, esophageal, colorectal, ovarian, and cervical cancer.
Associated with increased risk of infection, bruising or bleeding, anemia, constipation, diarrhea, nausea, peripheral neuropathy, asthenia, phlebitis and rarely hyponatremia.
Less common effects are hair loss and allergic reaction.